Tag:
New Enterprise Associates
Latest Headlines
Latest Headlines
UPDATED: Upstart Ra sheds stealth status, targets new drug class
Two years after Ra snagged an initial $10 million in venture cash, the company has hauled in a second tranche of $8.6 million and picked its disease target: hereditary angioedema, a rare and lethal immune system disorder.
NEA turns to Europe in $30M round for RNA-drug developer Prosensa
The Dutch biotech Prosensa has rounded up 23 million euros--about $30 million--in a new round earmarked to back its work on RNA drug development for Duchenne muscular dystrophy and other rare
MedImmune's Mott starts new career in VC
MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he
